AKRO - NASDAQ
Akero Therapeutics, Inc.
$54.65
+0.0000%Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAkero Therapeutics, Inc. Management Team
Mr. Scott A. Gangloff
Chief Technical Officer
Compensation
$558,641
Dr. Timothy Rolph Ph.D.
Co-Founder & Chief Scientific Officer
Compensation
$722,315
Dr. Jonathan M. Young J.D., Ph.D.
Co-Founder, Executive Vice President, Chief Operating Officer & Secretary
Compensation
$710,500
Ms. Catriona Yale
Executive Vice President & Chief Development Officer
Compensation
$716,300
Mr. William R. White J.D.
Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development
Compensation
$739,500
Dr. Andrew Cheng M.D., Ph.D.
President, Chief Executive Officer & Director
Compensation
$1,097,600
Mr. John J. Schembri
Senior Vice President & Head of Finance
Mr. Thomas Ross
Senior Vice President & Head of Legal
Mr. Patrick Lamy
Senior Vice President of Commercial Strategy
Akero Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.05M worth of AKRO shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
39.7K
2.06M
-2.1M
-$2.06M
9-12 Months
0
0.00
93.4K
4.99M
-5.0M
-$4.99M
Top Buyers
No buying activity
Top Sellers
Cheng Andrew
Director, Officer: President And Ceo
$3.30M
Rolph Timothy
Officer: Chief Scientific Officer
$2.16M
Young Jonathan
Officer: Chief Operating Officer
$509K
Yale Catriona
Officer: Chief Development Officer
$391K
White William Richard
Officer: Chief Financial Officer
$269K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.05M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
AKRO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | April 26, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 27, 2020 | June 01, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.